» Articles » PMID: 22538804

Examination of the Carbon Monoxide Diffusing Capacity (DL(CO)) in Relation to Its KCO and VA Components

Overview
Specialty Critical Care
Date 2012 Apr 28
PMID 22538804
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

The single-breath carbon monoxide diffusing capacity (DL(CO)) is the product of two measurements during breath holding at full inflation: (1) the rate constant for carbon monoxide uptake from alveolar gas (kco [minute(-1)]) and (2) the "accessible" alveolar volume (Va). kco expressed per mm Hg alveolar dry gas pressure (Pb*) as kco/Pb*, and then multiplied by Va, equals Dl(CO); thus, Dl(CO) divided by Va (DL(CO)/Va, also called Kco) is only kco/Pb* in different units, remaining, essentially, a rate constant. The notion that DL(CO)/Va "corrects" DL(CO) for reduced Va is physiologically incorrect, because DL(CO)/Va is not constant as Va changes; thus, the term Kco reflects the physiology more appropriately. Crucially, the same DL(CO) may occur with various combinations of Kco and Va, each suggesting different pathologies. Decreased Kco occurs in alveolar-capillary damage, microvascular pathology, or anemia. Increased Kco occurs with (1) failure to expand normal lungs to predicted full inflation (extrapulmonary restriction); or (2) increased capillary volume and flow, either globally (left-to-right intracardiac shunting) or from flow and volume diversion from lost or damaged units to surviving normal units (e.g., pneumonectomy). Decreased Va occurs in (1) reduced alveolar expansion, (2) alveolar damage or loss, or (3) maldistribution of inspired gases with airflow obstruction. Kco will be greater than 120% predicted in case 1, 100-120% in case 2, and 40-120% in case 3, depending on pathology. Kco and Va values should be available to clinicians, as fundamental to understanding the clinical implications of DL(CO). The diffusing capacity for nitric oxide (DL(NO)), and the DL(NO)/DL(CO) ratio, provide additional insights.

Citing Articles

Diaphragm dysfunction: how to diagnose and how to treat?.

Jesus F, Hazenberg A, Duiverman M, Wijkstra P Breathe (Sheff). 2025; 21(1):240218.

PMID: 40012556 PMC: 11864072. DOI: 10.1183/20734735.0218-2024.


Recent developments in connective tissue disease associated pulmonary arterial hypertension.

Rodolfi S, Ong V, Denton C Int J Cardiol Congenit Heart Dis. 2024; 16:100513.

PMID: 39712533 PMC: 11657338. DOI: 10.1016/j.ijcchd.2024.100513.


Celebrating women in physiology: Marie Krogh and the single-breath technique for measuring pulmonary diffusing capacity.

Berg R Exp Physiol. 2024; 109(12):1987-1991.

PMID: 39561379 PMC: 11607610. DOI: 10.1113/EP092377.


Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.

Pott H, Weckler B, Gaffron S, Martin R, Maier D, Alter P Respirology. 2024; 30(2):134-146.

PMID: 39448064 PMC: 11788467. DOI: 10.1111/resp.14843.


Beyond the Spirometry: New Diagnostic Modalities in Chronic Obstructive Pulmonary Disease.

Song J, Kim Y Tuberc Respir Dis (Seoul). 2024; 88(1):1-13.

PMID: 39308278 PMC: 11704728. DOI: 10.4046/trd.2024.0040.